List of Excipients in Branded Drug GLUCOTROL

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Roerig	GLUCOTROL	glipizide	0049-0170	CELLULOSE ACETATE
Roerig	GLUCOTROL	glipizide	0049-0170	FERRIC OXIDE RED
Roerig	GLUCOTROL	glipizide	0049-0170	HYPROMELLOSE
Roerig	GLUCOTROL	glipizide	0049-0170	MAGNESIUM STEARATE
Roerig	GLUCOTROL	glipizide	0049-0170	POLYETHYLENE GLYCOL
Roerig	GLUCOTROL	glipizide	0049-0170	SODIUM CHLORIDE
Roerig	GLUCOTROL	glipizide	0049-1620	CELLULOSE ACETATE

Glucotrol Excipient Strategy and Commercial Opportunities for Glipizide Products

Last updated: August 23, 2026

Glucotrol contains glipizide, a second-generation sulfonylurea used with diet and exercise to improve glycemic control in adults with type 2 diabetes. The commercial opportunity is concentrated in two formulation platforms: immediate-release glipizide tablets and Glucotrol XL extended-release tablets. Immediate-release products are relatively accessible through conventional tableting and generic competition. Glucotrol XL requires greater control over osmotic release, membrane coating, dose uniformity, and in-vitro drug release.

The strongest excipient opportunities are in direct-compression systems, modified-release polymers, coating technologies, low-cost generic manufacturing, patient-focused formulations, and differentiated regulatory submissions. The main commercial constraint is that glipizide is an established generic active ingredient with limited ability to command premium pricing without a meaningful formulation, adherence, tolerability, or manufacturing advantage.

What is Glucotrol and which formulations are commercially relevant?

Glucotrol is the brand name for glipizide, marketed by Pfizer. Two dosage-form platforms are commercially relevant:

Product	Active ingredient	Release profile	Typical strengths	Main formulation challenge
Glucotrol	Glipizide	Immediate release	5 mg, 10 mg	Content uniformity and rapid disintegration
Glucotrol XL	Glipizide	Extended release	2.5 mg, 5 mg, 10 mg	Controlled osmotic delivery and release reproducibility

Glipizide is a low-dose, poorly water-soluble active pharmaceutical ingredient. The low dose increases the importance of blend uniformity, segregation control, and assay precision. The active ingredient has a molecular weight of approximately 445.6 g/mol and is administered orally before meals or according to the product label.[1]

Glucotrol XL uses an extended-release delivery system rather than a simple matrix tablet. The product is designed to release glipizide gradually over approximately 24 hours. The tablet uses osmotic principles involving a semipermeable membrane and controlled water influx.[2]

What excipients are used in Glucotrol immediate-release tablets?

The Glucotrol immediate-release label identifies a conventional solid oral formulation containing excipients used for dilution, flow, compression, disintegration, and lubrication.[1]

Excipient category	Representative excipients in the labeled product	Functional role
Diluent	Lactose	Increases tablet mass and supports content uniformity
Filler and compression aid	Microcrystalline cellulose	Improves compactibility and tablet strength
Glidant	Colloidal silicon dioxide	Improves powder flow and reduces manufacturing variability
Disintegrant	Sodium starch glycolate	Promotes tablet breakup after ingestion
Lubricant	Stearic acid	Reduces tooling friction and ejection force

The formulation is compatible with standard wet-granulation or direct-compression manufacturing strategies, depending on particle-size distribution, bulk density, and flow properties of the selected glipizide active ingredient and excipients.

Which excipients are most important for immediate-release glipizide?

Content uniformity is the primary technical issue. Because glipizide is present at a low dose relative to total tablet weight, the excipient system must prevent segregation during blending, transfer, and compression.

Microcrystalline cellulose and lactose can provide a balanced filler system. Lactose improves manufacturability and tablet economics, while microcrystalline cellulose contributes compactibility and disintegration. Excessive use of hydrophobic lubricant can delay dissolution, making lubricant level and blending time important development variables.

Sodium starch glycolate is commercially attractive because it supports rapid tablet breakup at relatively low use levels. Alternatives include crospovidone and croscarmellose sodium. A reformulated generic product could use these alternatives to improve dissolution robustness, reduce dependence on a particular supplier, or support a lactose-free claim.

What excipients are used in Glucotrol XL extended-release tablets?

Glucotrol XL uses excipients associated with osmotic drug delivery and controlled membrane transport. The FDA labeling identifies polyethylene oxide, sodium chloride, hypromellose, magnesium stearate, cellulose acetate, and polyethylene glycol among the inactive ingredients.[2]

Excipient	Likely formulation function
Polyethylene oxide	Osmotic push layer and controlled swelling
Sodium chloride	Osmotic agent that drives water influx
Hypromellose	Binder, hydrophilic polymer, or release-supporting matrix component
Magnesium stearate	Lubricant
Cellulose acetate	Semipermeable membrane
Polyethylene glycol	Membrane pore former or coating modifier

The commercial value of this system is higher than that of the immediate-release formulation because the excipients determine the drug-release mechanism. Small changes in polymer molecular weight, particle size, substitution grade, coating weight gain, membrane permeability, and osmogen loading can affect the dissolution profile.

How does the Glucotrol XL osmotic system work?

The tablet membrane permits water to enter the dosage form while limiting uncontrolled passage of dissolved contents. Water hydrates the internal polymer system and generates pressure. The drug is then released through a delivery orifice at a controlled rate.

The critical quality attributes include:

• Membrane thickness and uniformity
• Cellulose acetate substitution and permeability
• Polyethylene oxide molecular weight and swelling behavior
• Sodium chloride concentration
• Orifice size and consistency
• Tablet hardness and core integrity
• Residual solvent and coating uniformity
• Release profile across pH conditions
• Dose dumping resistance under alcohol and food conditions

These requirements make Glucotrol XL-style products more difficult to replicate than immediate-release glipizide tablets. A generic manufacturer must establish pharmaceutical equivalence and demonstrate bioequivalence under the applicable FDA requirements. Modified-release products commonly require more extensive dissolution characterization than immediate-release products.[3]

What excipient strategies have the greatest commercial potential?

1. Direct-compression platforms for generic glipizide

The most accessible opportunity is a robust direct-compression blend using:

• Microcrystalline cellulose
• Lactose or mannitol
• Crospovidone or croscarmellose sodium
• Colloidal silicon dioxide
• Magnesium stearate or stearic acid

A direct-compression product can reduce granulation energy, shorten processing time, and simplify equipment requirements. The principal development risks are low-dose homogeneity, powder segregation, poor flow, and dissolution changes caused by lubricant overmixing.

Excipient suppliers can create value through co-processed filler-disintegrant systems designed for low-dose drugs. These materials can offer more consistent flow and compaction than a simple physical blend.

2. Lactose-free or low-lactose products

A lactose-free formulation could target patients with lactose intolerance, institutional formularies with excipient restrictions, and manufacturers seeking simplified global product portfolios. Mannitol, anhydrous dibasic calcium phosphate, or a cellulose-based filler could replace lactose.

The replacement is not technically neutral. Mannitol can improve mouthfeel and provide a premium excipient profile, but it may change tablet tensile strength and dissolution. Dibasic calcium phosphate can improve hardness but may create compatibility or dissolution considerations. A cellulose-based system may provide better disintegration but increase tablet size.

A lactose-free claim would require control of cross-contamination and a clear regulatory basis. It would not, by itself, create strong market exclusivity.

3. Extended-release polymer and membrane systems

The strongest technical opportunity is in Glucotrol XL-compatible extended-release systems. Potential approaches include:

• Osmotic tablets using polyethylene oxide and cellulose acetate
• Hydrophilic matrix tablets using hypromellose
• Combination matrix systems using hypromellose and polyethylene oxide
• Coated multiparticulates using ethylcellulose or acrylic polymers
• Gastroretentive or erosion-controlled systems, subject to clinical and regulatory justification

An osmotic system may offer the most direct technical match to the branded product, but it requires specialized coating and laser-drilling or precision-orifice capabilities. A matrix tablet may reduce manufacturing complexity but could produce a different release mechanism and require a more demanding bioequivalence strategy.

Polyethylene oxide grade selection is a major commercial lever. High-molecular-weight grades provide stronger swelling and push-layer performance, while lower grades may reduce viscosity and improve processing. Supplier qualification is important because polymer rheology and particle-size differences can shift release.

4. Co-processed excipients for manufacturing consistency

Co-processed excipients can combine a filler, binder, disintegrant, and flow aid in a single engineered material. For glipizide, this may improve:

• Low-dose blend uniformity
• Tablet weight control
• Compression speed
• Tablet tensile strength
• Disintegration consistency
• Scale-up reproducibility

The opportunity is strongest for contract manufacturers and small generic companies that lack extensive formulation-development infrastructure. The commercial proposition is process robustness rather than clinical differentiation.

5. Patient-centered dosage forms

Potential differentiated products include:

• Smaller tablets
• Scored immediate-release tablets
• Orally disintegrating tablets
• Sprinkle-compatible dosage forms
• Modified-release tablets with improved swallowability

The commercial case must be supported by a defined patient or caregiver need. Glipizide has hypoglycemia risk as a pharmacologic class effect, so a formulation change that improves convenience without changing exposure may have limited value unless it improves adherence or reduces administration errors.

Orally disintegrating glipizide products would require careful control of taste, dose uniformity, friability, and rapid wetting. Mannitol, crospovidone, low-substituted hydroxypropyl cellulose, and flavor systems could support development, but the dosage form may not justify a substantial premium in a price-sensitive generic market.

When does Glucotrol lose exclusivity?

Glucotrol and Glucotrol XL are established products. Their core regulatory and formulation exclusivity periods have expired, and multiple generic glipizide products have been approved in the United States.[3][4]

Exclusivity category	Current commercial position
New chemical entity exclusivity	Expired
Original immediate-release product protection	Expired
Original extended-release product protection	Expired or no longer commercially blocking
Generic immediate-release entry	Established
Generic extended-release entry	Established, subject to product-specific approval
Formulation-specific future protection	Possible only through new qualifying intellectual property

A new excipient system would not automatically create patent protection. Patentable subject matter could include a defined polymer ratio, membrane composition, release profile, manufacturing process, particle engineering approach, or stability improvement. The claims would need to provide technical differentiation over prior glipizide formulations.

What is the Orange Book status of Glucotrol and Glucotrol XL?

The FDA Orange Book identifies approved drug products and, where applicable, listed patents and exclusivity information. Glucotrol and Glucotrol XL should be evaluated through the current Orange Book entries rather than relying on historical patent summaries because listed patents, therapeutic equivalence codes, and marketing status can change.[4]

For a commercial diligence review, the relevant checks are:

1. Whether the branded reference listed drug remains active.
2. Which strengths have approved generic equivalents.
3. Whether each generic has an AB therapeutic equivalence rating.
4. Whether any currently listed patents remain relevant.
5. Whether a proposed product requires an ANDA, 505(b)(2) application, or another pathway.
6. Whether the proposed formulation is therapeutically equivalent to the reference product.

For a conventional generic matching the reference dosage form and strength, the likely pathway is an abbreviated new drug application. A materially different delivery system may require a 505(b)(2) application and additional clinical or pharmacokinetic support.

Which companies are challenging Glucotrol through generic competition?

Glipizide generic competition is established across multiple manufacturers and marketing authorization holders. The competitive set typically includes large generic companies, specialty manufacturers, and contract manufacturing organizations with approved or licensed products.

Competition is based primarily on:

• Wholesale acquisition cost
• Supply reliability
• Approved strengths
• Therapeutic equivalence
• Manufacturing scale
• Formulary access
• Product discontinuation risk
• Ability to support multiple markets

Immediate-release glipizide is likely to face stronger price erosion because the formulation is technically simple and multiple suppliers can manufacture it. Extended-release glipizide has higher entry barriers because dissolution performance, manufacturing controls, and bioequivalence requirements are more demanding.

What Paragraph IV challenges and patent litigation affect Glucotrol?

Paragraph IV risk is most relevant when a generic applicant certifies that a listed patent is invalid, unenforceable, or will not be infringed. The commercial relevance of a Paragraph IV filing depends on whether an Orange Book-listed patent remains active and whether the reference product sponsor files an infringement action within the statutory period.

For Glucotrol and Glucotrol XL, the principal modern risk is not an active branded patent blockade but the possibility of product-specific disputes involving:

• Release-control mechanisms
• Membrane compositions
• Drug-delivery orifices
• Polymer grades or ratios
• Manufacturing processes
• Narrow formulation claims
• 505(b)(2) products that do not fully match the reference product

No current litigation conclusion should be inferred solely from historical Glucotrol patent activity. Patent status must be checked against the current Orange Book and court records before launch or licensing decisions.

How strong is the Glucotrol patent estate?

The legacy patent estate is commercially weak against ordinary generic entry because glipizide is an established active ingredient and the main products have been exposed to generic competition for years.

A new formulation patent estate could be stronger if it includes:

• Narrow but reproducible release specifications
• A non-obvious osmotic membrane composition
• Improved alcohol resistance
• A demonstrated stability advantage
• Lower tablet-size requirements at equivalent exposure
• A manufacturing process that materially improves content uniformity
• A technically defined polymer architecture

Patent strength will depend on claim breadth, prior-art density, enablement, written description, and the ability to demonstrate unexpected performance. Broad claims to glipizide plus common excipients are unlikely to provide durable protection.

What manufacturing and intellectual-property barriers exist?

Immediate-release products

Manufacturing barriers are low to moderate. The main operational risks are:

• Low-dose blend uniformity
• Segregation during scale-up
• Lubrication sensitivity
• API particle-size variation
• Tablet capping or friability
• Dissolution variability

A manufacturer with standard high-shear granulation, roller compaction, or direct-compression equipment can usually address these risks.

Extended-release products

Manufacturing barriers are moderate to high. Critical capabilities include:

• Controlled polymer processing
• Uniform tablet-core compression
• High-quality film coating
• Membrane weight-gain control
• Orifice formation
• In-process release testing
• Robust dissolution modeling
• Scale-up validation

The most defensible intellectual property is likely to arise from the interaction between excipient composition and manufacturing parameters rather than from the use of a common excipient alone.

How does Glucotrol compare with other second-generation sulfonylureas?

Product	Active ingredient	Formulation opportunity	Generic barrier
Glucotrol	Glipizide	Immediate-release tablets, patient-centered dosage forms	Low
Glucotrol XL	Glipizide	Osmotic or polymer-controlled release	Moderate to high
Micronase	Glyburide	Immediate-release and micronized formulations	Low to moderate
Amaryl	Glimepiride	Low-dose tablets and fixed-dose combinations	Low to moderate
Diabeta	Glyburide	Conventional oral tablets	Low

Glipizide’s low-dose profile makes blend uniformity more demanding than for higher-dose products. Glucotrol XL offers a more technically attractive excipient opportunity than immediate-release glipizide because the release system creates room for formulation engineering. The market, however, remains sensitive to generic pricing and the clinical availability of newer diabetes therapies.

What revenue exposure and commercial opportunities exist?

Revenue exposure for a branded Glucotrol-style product is limited by generic substitution and the availability of newer type 2 diabetes therapies, including metformin, DPP-4 inhibitors, SGLT2 inhibitors, GLP-1 receptor agonists, and insulin products.

The most realistic commercial opportunities are:

Opportunity	Revenue potential	Development risk	Commercial assessment
Low-cost immediate-release generic	Low to moderate	Low	Volume-driven
Extended-release generic	Moderate	Moderate to high	Better technical barrier
Lactose-free reformulation	Low	Low to moderate	Niche opportunity
Orally disintegrating tablet	Moderate	Moderate	Requires adherence rationale
Specialty co-processed excipient platform	Moderate	Moderate	B2B opportunity
505(b)(2) differentiated delivery system	Moderate to high	High	Requires clinical and regulatory investment
Global supply or licensing deal	Moderate	Moderate	Attractive where local supply is limited

An excipient supplier may have a better risk-adjusted opportunity than a finished-dose manufacturer. Selling a validated low-dose direct-compression platform or an osmotic-release polymer system to multiple generic manufacturers can diversify revenue across products and territories.

What licensing deals are commercially plausible?

Potential licensing structures include:

• Excipient technology licenses to generic drug manufacturers
• Formulation-development partnerships with contract development and manufacturing organizations
• Regional commercialization rights for extended-release glipizide
• Supply agreements for pharmaceutical-grade polyethylene oxide, cellulose acetate, or co-processed excipients
• Technology-transfer deals covering coating, orifice formation, or dissolution-control processes

A license based only on a common excipient is unlikely to command significant economics. The licensor should package the excipient with formulation know-how, process parameters, analytical methods, scale-up data, and regulatory documentation.

What generic launch scenarios exist?

Immediate-release launch

A conventional ANDA launch would face established competition and likely price pressure. The best entry position would involve reliable supply, multiple strengths, efficient tablet manufacture, and a differentiated excipient claim such as lactose-free or improved stability.

Extended-release launch

An extended-release ANDA or 505(b)(2) product could obtain better pricing if it demonstrates reliable equivalence and secures supply before additional competitors enter. Development timelines and regulatory risk would be higher because dissolution and pharmacokinetic performance must remain tightly controlled.

Reformulated lifecycle product

A reformulated product could target a smaller but more defensible segment through tablet-size reduction, improved swallowability, alternative excipient composition, or a delivery profile designed for a specific patient population. The product would need a clear clinical or commercial reason to avoid being treated as a non-differentiated reformulation.

What geographic coverage matters for glipizide excipients and products?

The United States remains important for Orange Book-listed products and ANDA competition. Europe, Canada, Japan, China, India, Latin America, and emerging markets may offer different opportunities because of:

• Local generic penetration
• National reimbursement policies
• Local manufacturing requirements
• Excipient monograph acceptance
• Pharmacopoeial standards
• Reference-product availability
• Registration requirements for modified-release products

A global excipient platform should account for USP-NF, Ph. Eur., JP, and other applicable standards. Supplier qualification and change-control documentation can determine whether a formulation transfers efficiently across jurisdictions.

Key Takeaways

• Glucotrol is glipizide; Glucotrol XL is the more technically attractive extended-release platform.
• Immediate-release glipizide supports low-cost generic and excipient-efficiency strategies, but competition is intense.
• Glucotrol XL depends on polymer swelling, osmotic pressure, membrane permeability, and controlled release.
• The most valuable excipient opportunities involve co-processed direct-compression systems and validated modified-release polymer platforms.
• A new excipient does not create meaningful exclusivity unless supported by narrow, defensible formulation or process claims.
• Generic entry is established, and legacy branded exclusivity does not provide a durable barrier.
• The most credible premium opportunities are extended-release equivalence, lactose-free products, smaller tablets, orally disintegrating systems, and B2B excipient technology licensing.
• Commercial success will depend more on manufacturing reliability, regulatory execution, and supply economics than on the use of a conventional excipient alone.

FAQs

Can lactose be replaced in a generic Glucotrol tablet?

Yes. Lactose may be replaced with mannitol, microcrystalline cellulose, dibasic calcium phosphate, or another suitable pharmaceutical filler, provided the product meets quality, dissolution, stability, and bioequivalence requirements.

Is polyethylene oxide essential for a Glucotrol XL generic?

Not necessarily. A generic may use a different formulation if it satisfies applicable pharmaceutical equivalence and bioequivalence requirements. Polyethylene oxide remains commercially attractive because it can reproduce an osmotic or swelling-controlled release mechanism.

Does a lactose-free glipizide product receive new market exclusivity?

No. Lactose-free status alone generally does not create regulatory exclusivity. Any patent protection would need to arise from a novel and non-obvious formulation or manufacturing feature.

Is Glucotrol XL more difficult to manufacture than immediate-release glipizide?

Yes. Extended-release products require tighter control of polymer properties, coating weight, membrane permeability, delivery-orifice consistency, and dissolution performance.

Can an excipient supplier patent a glipizide formulation?

Potentially, but protection is more likely for a defined excipient combination, polymer architecture, release profile, process, or stability result than for the use of a conventional excipient with glipizide.

References

1. Pfizer Inc. (2023). Glucotrol (glipizide) tablets prescribing information. U.S. Food and Drug Administration.

2. Pfizer Inc. (2023). Glucotrol XL (glipizide extended-release tablets) prescribing information. U.S. Food and Drug Administration.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.

4. U.S. Food and Drug Administration. (2024). Guidance for industry: Bioequivalence studies with pharmacokinetic endpoints for drugs submitted under an ANDA. U.S. Department of Health and Human Services.